Form 4: Mirum Pharma COO Granted Significant Equity Awards

Mirum Pharmaceuticals' President and COO, Peter Radovich, received substantial equity awards including stock options, restricted stock units, and performance-based units.

Summary

• Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc. (MIRM), acquired various derivative securities on January 28, 2026.
• The awards include 25,120 stock options with an exercise price of $100.85, vesting over approximately four years.
• An additional 16,280 Restricted Stock Units (RSUs) were granted, vesting in three equal annual installments starting January 28, 2027.
• 34,500 Performance Restricted Stock Units (PSUs) were also granted, with performance criteria determined to have been met on January 28, 2026.
• The PSUs will vest in two tranches: 2/3 on March 15, 2026, and 1/3 on March 15, 2027.
• The stock options have an expiration date of January 27, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with shareholder interests through significant equity grants. It reflects ongoing executive commitment and the achievement of performance criteria for PSUs, though it does not directly report on financial performance.

Positives

• The significant equity grants align the interests of the President and COO with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for stock options and restricted stock units promote executive retention over several years.
• The vesting of performance-based units indicates that specific company performance criteria have been successfully met, which is a positive operational indicator.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the specified vesting schedules for the equity awards.

Industry Context

StockSavvy.ai notes that significant equity grants to top executives like a President and COO are a standard practice in the biotechnology and pharmaceutical industry. These grants are designed to attract, retain, and motivate key talent, aligning their long-term financial interests with the company's performance and shareholder value creation. The mix of stock options, time-based RSUs, and performance-based PSUs reflects a comprehensive compensation strategy aimed at balancing retention with performance incentives.

Comparison to Industry Standards

• The structure of equity compensation, including stock options, time-based RSUs, and performance-based PSUs, is consistent with common practices among publicly traded pharmaceutical companies of similar market capitalization and development stage.
• The vesting schedules, particularly the multi-year vesting for options and RSUs, are typical for executive compensation packages in the biotech sector, aiming for long-term commitment.
• The inclusion of performance-based units, with criteria already met, suggests a focus on achieving specific operational or financial milestones, a trend seen in companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals where executive incentives are tied to drug development progress or revenue targets.

Related Party Transactions

• The reported transactions represent equity awards granted by Mirum Pharmaceuticals, Inc. to its President and COO, Peter Radovich, which are considered related party transactions due to his executive position.

Stakeholder Impact

• Shareholders: The equity grants align management's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions and improved company performance.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• Continued vesting of stock options according to the schedule: 1/4th one year after January 28, 2026, and the balance in 36 successive equal monthly installments.
• Continued vesting of Restricted Stock Units (RSUs) on each anniversary of January 28, 2026, for three years.
• Vesting of Performance Restricted Stock Units (PSUs) with 2/3 on March 15, 2026, and 1/3 on March 15, 2027.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Peter Radovich, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Grant, Executive Compensation, Insider Transaction, Form 4